If remote visits are planned in both decentralized and hybrid trials, how precisely do the televisits work and how beneficial can this really be to study patients, site staff, and sponsors?

Regulators now prioritize fit-for-purpose data over legacy instrument brand names. Modernizing your assessment strategy reduces licensing delays and improves trial startup speed and efficiency.

With the FDA stating last fall that the “patient’s voice” is key to understanding real-world-impacts, eCOAs and ePROs are becoming quintessential tools for cancer trials.

A site-focused strategy drove strong eConsent adoption in a complex women’s health study, showing how tailored training and hands-on support boost engagement and compliance.

A truly integrated eSource Solution, including DDC, eCOA, and eConsent, facilitates remote or decentralized clinical trials by ingesting data from multiple sources and consolidating it into a single data set.

Despite the rise of digital solutions in healthcare, paper consent forms are still common in today’s clinical trials. Unfortunately, these paper forms pose significant challenges in retaining the documentation of informed consent for centrally stored biospecimens.

With the FDA stating last fall that the “patient’s voice” is key to understanding real-world-impacts, eCOAs and ePROs are becoming quintessential tools for cancer trials.

This comprehensive overview highlights the critical role these platforms play in modern clinical research, emphasizing their impact on data integrity and trial efficiency.

Get an overview of SISCAPA's utilization of eTechnologies, specifically ePRO, and how their partnership with CDS accurately demonstrates the improvement of data collection and analysis in the biotechnology industry.